Navigation Links
New MedPredict Report Highlights Trend Toward Early Diagnosis and Treatment of Rheumatoid Arthritis, Impact on Pharmaceutical Development
Date:7/8/2008

SCOTTSDALE, Ariz., July 8 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for Rheumatoid Arthritis (RA) therapies.

In this report, entitled Thought Leader Insight & Analysis: Rheumatoid Arthritis Q2 2008, MedPredict's global Thought Leader Panel reviews progress in developing biological and small molecule regimens for the treatment of early RA.

According to this report, the key change in practice occurring in the treatment of RA is the push toward earlier diagnosis and treatment, which is associated with more durable remission. New biomarkers and approaches to cellular imaging in early disease are also being investigated.

"Our Panel sheds light on which companies are likely to be positioned to capitalize on this trend," says MedPredict President Jeffrey D. Berk. "In addition, they offer predictions on how tocilizumab, certolizumab and golimumab will compete with the established biologicals, and how the current market leaders are positioning to defend their brands in the RA space. Their discussion will provide essential strategic and competitive insight for anyone with a stake in this market."

The report also addresses pain management in RA, provides a postmortem on the rituximab non-renal lupus trial, and discusses the most meaningful clinical developments related to the following mechanisms: Anti-TNF, Anti-CTLA, Anti-IL-1, Anti-IL-6, Antiresorptives, Anti-IL-17, p38 MAP kinase, JAK, Syk, PDE5, and more.

Companies mentioned in this report include: Abbott, Amgen, Amgen/Takeda Bio, Amgen/Wyeth, AstraZeneca/MedImmune, Biogen, Bristol-Myers Squibb, Celgene, Centocor, Centocor/Schering-Plough/Essex, GlaxoSmithKline/Genmab, Human Genome Sciences, Incyte, Merck Serono/ZymoGenetics, Novartis, Oxypharma, Pfizer, Roche/Chugai, Roche/Genentech, Sanofi-Aventis/Regeneron, UCB, Vertex and Wyeth/Trubion.

MedPredict conducted in-depth, primary interviews with leading rheumatologists from North America and Europe to provide the basis for this report.

This report can be purchased by contacting MedPredict.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict Market Research
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. In Pain Market, Huge Unmet Needs, Tough Regulatory Environment Challenge Pharmaceutical Companies, According to MedPredict
2. Thought Leaders Discuss Positive Outlook for Bapineuzumab in Alzheimers Disease in MedPredict Report
3. New MedPredict Report Suggests Market for Alcoholism Therapies is Underestimated
4. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
5. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
6. Knowledge Enterprises, Inc. and The Institute for Orthopaedics(TM) Release The 2007-2008 Orthopaedic Industry Annual Report
7. Galaxy Nutritional Foods Reports FY2008 Results
8. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
9. Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter
10. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
11. Dermatologists Report Increased Use of Biologics in the Treatment of Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... MAYNARD, Mass. , Jan. 19, 2017 ... company focused on enhancing productivity in aquaculture and a ... ), announces that it has completed the listing of ... finalized the equity subscription from Intrexon. "AquaBounty,s ... Company that will broaden our exposure to the U.S. ...
(Date:1/19/2017)... ... 2017 , ... DaVita Clinical Research (DCR), a ... device development, and Prism Clinical Research , a leader in providing fully ... Clinical Trials (VCT) has been selected by both companies as an exclusive ...
(Date:1/19/2017)... BD (Becton, Dickinson and Company) (NYSE: BDX ), a ... live webcast of its Annual Meeting of Shareholders on Tuesday, January ... can be accessed from the BD corporate website at http://www.bd.com/investors/ ... ... BD is a global medical technology company that is ...
(Date:1/18/2017)... LINCOLN, Mass. , Jan. 18, 2017 /PRNewswire/ ... in applying mechanistic modeling to drug research and ... , PhD, Co-Founder, President, and CEO of Applied ... Group for Informatics and Modeling (BAGIM) Meeting on ... in Cambridge , MA.   Dr. ...
Breaking Biology Technology:
(Date:1/11/2017)... 2017 Intoxalock, a leading ignition interlock provider, ... its patent-pending calibration device. With this new technology, Intoxalock ... upload data logs and process repairs at service center ... "Fighting drunk driving through the application of cutting-edge technologies ... but also for the customer who can get back ...
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, ... studies in healthy volunteers of a novel calcium ... treat acute pancreatitis. Acute pancreatitis, ... a mild disorder, but can be very serious.  In ... and sepsis, where extended hospital stays, time in ...
(Date:1/6/2017)... 5, 2017  Delta ID Inc., a leader in ... for automotive at CESĀ® 2017. Delta ID has collaborated ... demonstrate the use of iris scanning as a secure, ... driver in a car, and as a way to ... Delta ID and Gentex will demonstrate (booth ...
Breaking Biology News(10 mins):